Inactive Instrument

Sierra Oncology, Inc.

SRRA

US82640U4040

Biotechnology & Medical Research

Sierra Oncology, Inc. has Changed its Ticker to SRRA from DNAI

January 10, 2017 at 10:30 am IST

Effective January 10, 2017, Sierra Oncology, Inc. changed its Nasdaq Global Market stock ticker symbol to SRRA from DNAI.

Latest news about Sierra Oncology, Inc.

Sierra Oncology, Inc. Announces Update on Sra737	06/23/06	CI
Sareum Holdings Says GSK Completes Acquisition of Sierra Oncology	04/22/04	DJ
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from NASDAQ Composite Index	04/22/04	CI
Sierra Oncology, Inc. Announces Executive Changes	02/22/02	CI
GSK Completes $1.9 Billion Purchase of Sierra Oncology	01/22/01	MT
GlaxoSmithKline plc completed the acquisition of Sierra Oncology, Inc. from Frazier Healthcare VI, L.P., Frazier Life Sciences VIII, L.P., Frazier Life Sciences Public Fund, L.P., all managed by Frazier Management, L.L.C., and others.	01/22/01	CI
Sierra Oncology Shareholders Approve Acquisition by GSK	30/22/30	MT
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Growth Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Completeness Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Growth Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell 3000E Value Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Comp Growth Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Growth Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Dynamic Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Growth Index	24/22/24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell Microcap Value Index	24/22/24	CI
Sierra Oncology Submits New Drug Application to FDA for Cancer Treatment Momelotinib	17/22/17	MT
Sierra Oncology, Inc. Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration	17/22/17	CI
Pfizer to sell stake in GSK's consumer health business after it lists	01/22/01	RE
GSK to spend up to $3.3 bln on Affinivax to boost vaccines roster	31/22/31	RE
Sierra Oncology, Inc. Announces Momelotinib Pivotal Phase 3 Data Receives Oral Presentation At American Society of Clinical Oncology Annual Meeting	27/22/27	CI

Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company's lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.62%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.20%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs